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Aims To assess whether AF is a risk factor for cognitive dysfunction we used prospective data on AF, repeat cognitive
scores, and dementia incidence in adults followed over 45 to 85 years.
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Methods
and results
Data are drawn from the Whitehall II study, N= 10 308 at study recruitment in 1985. A battery of cognitive tests
was administered four times (1997–2013) to 7428 participants (414 cases of AF), aged 45–69 years in 1997.
Compared with AF-free participants, those with longer exposure to AF (5, 10, or 15 years) experienced faster cog-
nitive decline after adjustment for sociodemographic, behavioural, and chronic diseases (P for trend = 0.01).
Incident stroke or coronary heart disease individually did not explain the excess cognitive decline; however, this
relationship was impacted when considering them together (P for trend 0.09). Analysis of incident dementia
(N= 274/9302 without AF; N= 50/912 with AF) showed AF was associated with higher risk of dementia in Cox
regression adjusted for sociodemographic factors, health behaviours and chronic diseases [hazard ratio (HR): 1.87;
95% confidence interval (CI): 1.37, 2.55]. Multistate models showed AF to increase risk of dementia in those free
of stroke (HR: 1.67; 95% CI: 1.17, 2.38) but not those free of stroke and coronary heart disease (HR: 1.29; 95% CI:
0.74, 2.24) over the follow-up.
...................................................................................................................................................................................................
Conclusion In adults aged 45–85 years AF is associated with accelerated cognitive decline and higher risk of dementia even at ages
when AF incidence is low. At least in part, this was explained by incident cardiovascular disease in patients with AF.
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Introduction
The incidence of atrial fibrillation (AF), a type of cardiac arrhythmia
which produces rapid and irregular heartbeat, rises steeply with age,1
and has major health consequences due to increased likelihood of
thrombo-embolic complications and heart failure. The risk of stroke
is increased as much as five-fold in patients with AF.2 Stroke is a risk
factor for dementia,3,4 and there is consistent evidence that AF
increases the risk of dementia, particularly in stroke patients.5 A
recent meta-analysis reported associations of AF with cognitive
impairment and dementia in those without stroke, although the asso-
ciations were weaker than in stroke patients.6
Much of the evidence on AF and cognitive impairment, including
studies in the recent systematic reviews,5,6 comes from data on the
elderly among whom both conditions are more common, and their
association might simply reflect manifestations of underlying systemic
vascular disease. Disentangling the direction of association in studies
on the elderly is complicated as bidirectional effects are common.
For example, in older adults dementia is a risk factor for stroke and
vice-versa.7,8 As the pathophysiological processes underlying demen-
tia unfold over a very long period prior to clinical onset,9 further evi-
dence of the importance of AF for cognitive decline and dementia
needs to examine whether AF at younger ages increases risk of accel-
erated cognitive decline and dementia.
* Corresponding author. Tel: þ33 (0)1 77 74 74 10, Email: Archana.Singh-Manoux@inserm.fr
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To address some of these complexities, we sought to examine
associations of incident AF with subsequent cognitive decline over
the 45 to 85 year age span. Our aim was to determine the potential
dose-response association of duration of exposure to AF on cogni-
tive decline, and whether stroke and coronary heart disease (CHD)
subsequent to AF mediated this association. We also examined
whether AF increased dementia risk, and the extent to which it was
mediated by stroke and CHD.
Methods
Study population
The Whitehall II study is an ongoing cohort study of persons originally
employed by the British civil service. A total of 10 308 persons (33%
women), aged 35–55 years, were recruited to the study over the years
1985–1988.10 All participants responded to a comprehensive question-
naire and underwent a uniform, structured clinical evaluation, consisting
of measures of anthropometry, cardiovascular and metabolic risk factors
and disease. Since the baseline medical examination, follow-up examina-
tions have taken place approximately every 5 years. Participant consent
and research ethics approvals (University College London (UCL) ethics
committee) are renewed at each contact; the latest approval was by the
Joint UCL/UCLH Committee on the Ethics of Human Research
(Committee Alpha), reference number 85/0938.
Assessment of AF
Two sources were used: a twelve-lead resting ECG (Mingorec, Siemens
Healthcare, Erlangen, Germany) at all 6 waves of data collection between
1985 and 2013, and interpreted for the presence of AF/flutter at the
University of Glasgow (Prof. Macfarlane). Coding was carried out inde-
pendently in duplicate by trained technicians; Minnesota codes 83x were
used to identify cases of AF.11 The second source was the national hospi-
tal episode statistics (HES) database on hospital day cases and inpatients,
using ICD9: 427.3 and ICD10: I48. The National Health Service (NHS) in
the United Kingdom provides most of the health care, and record linkage
is based on encrypted values of the NHS number, unique for each
person.
Cognitive function
The cognitive test battery was introduced to the study in 1997 and data
are available at four assessments until 2013. The tests, described below,
provide a comprehensive assessment of cognitive function and are appro-
priate for this population composed of individuals younger than in most
studies on cognitive ageing.12
• Memory was assessed using a 20-word free recall test. Participants
were presented a list of one or two syllable words at two second
intervals and were then asked to recall in writing as many of the
words in any order with two minutes to do so.
• Reasoning, assessed via the Alice Heim 4-I test which is composed
of a series of 65 verbal and mathematical reasoning items of
increasing difficulty.13 It tests inductive reasoning, measuring the
ability to identify patterns and infer principles and rules.
Participants had 10 minutes to do this section.
• Verbal fluency, measures of phonemic and semantic fluency were
used.14 Participants were asked to recall in writing as many words
beginning with ‘s’ (phonemic fluency) and as many animal names
(semantic fluency) as they could. One minute was allowed for
each test and the scores combined for the analysis.
A global cognitive score was created using all tests by first standardizing
the raw scores to z-scores [mean = 0; standard deviation (SD) = 1] and
then averaging and standardizing them.
Dementia
We used comprehensive tracing of electronic health records using three
databases: HES, Mental Health Services Data Set (MHSDS) and the mor-
tality register. Record linkage until 3Ist of March 2015, using ICD-10
codes F00, F01, F02, F03, F05.1, G30, G31.0, G31.1, and G31.8 identified
cases of dementia. MHSDS is a national database which contains informa-
tion for persons in contact with mental health services in hospitals, outpa-
tient clinics, and the community. Mortality data were drawn from the
British national mortality register. The validity of dementia ascertainment
in our study is supported by findings on changes in the global cognitive
score, showing accelerated decline in global cognitive score in the 8–10
years before dementia diagnosis (Supplementary material online, Figure
S1). This is in agreement with previous studies that used a ‘gold-standard’
dementia ascertainment procedure.15
Covariates
Socio-demographic measures included age, sex, ethnicity (white, non-
white), and education (lower secondary school or less, higher secondary
school (usually achieved at age 18), and university or higher degree).
Analyses were also adjusted for health behaviours assessed by question-
naire, including smoking (current-, ex-, never-smoker); alcohol consump-
tion (units of alcohol consumed in a week: no/occasional alcohol
consumption, moderate alcohol consumption (1–14 (21)units/week in
women (men), and heavy alcohol consumption (>_14 (21) units in women
(men)); physical activity categorized as active (>_2.5 h/week of moderate
physical activity or >_1 h/week of vigorous physical activity), inactive
(<1 h/week of moderate and vigorous activity), and intermediate level of
activity for all others; and dietary behaviour self-reported frequency of
fruit and vegetable consumption (<once a day, once a day, >once a day).
Chronic diseases included were hypertension (systolic/diastolic 140/
90 mmHg or antihypertensive medication), prevalent diabetes mellitus
(fasting glucose >_ 7.0 mmol/L, a 2-h post-load glucose >_ 11.1 mmol/L,
doctor-diagnosed diabetes, diabetes medication), heart failure (ICD
codes: I50), coronary heart disease (CHD, ICD codes: I20–I25), stroke
(ICD codes: I60–I64), and self-reported use of medication for cardiovas-
cular disease.
Statistical analysis
We examined associations between AF and participant characteristics in
1997–1999. Flow chart of persons included in the analyses described
below is shown in Supplementary material online, Figure S2.
Analysis of cognitive decline
Mixed-effects models,16 with AF duration as a time varying covariate was
used to estimate differences in cognitive decline between those without
AF to those with AF exposure for 5, 10, and 15 years. The basic model
(Model 1) contained time (here age, centred at 65 years), time squared,
years since incident AF (0 = no AF, in years for those with AF), sex, eth-
nicity, education, and year of birth. Subsequent analyses (Model 2) were
adjusted for health behaviours and chronic diseases in 1997–1999.
Further analyses examined the mediating roles of stroke (Model 3), CHD
(Model 4), and both stroke and CHD (Model 5) by including them as
time varying covariates (1997 to 2013) in the analysis. The model yielded
mean effects for AF duration; subsequently an interaction term with age
and age2 was used to assess whether these effects varied as a function of
age.
2 A. Singh-Manoux et al.
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Analysis of incident dementia
We first used Cox regression to analyse the association of AF with inci-
dence of dementia. Participants were followed from 1985 until the
record of dementia, death, or March 31st 2015, whichever came first.
Age was the time scale and analyses adjusted for sex, ethnicity, and educa-
tion (Model 1) and then for health behaviours and chronic diseases at
baseline (Model 2).
In subsequent analyses, we examined the mediating role of stroke and
CHD over the follow-up in the association between AF and incidence of
dementia. These analyses were carried out using multistate models with a
Weibull distribution. These models are an extension of competing risks
survival analysis, allowing simultaneous estimation of the risk associated
with AF in a) the incidence of stroke, b) the risk of dementia in those with
stroke, and c) the risk of dementia in those free of stroke. Age was used
as the timescale, and models were adjusted for sociodemographic factors,
health behaviours, and chronic diseases at baseline. We repeated the
analyses replacing stroke with CHD and then with CVD (stroke and
CHD). These analyses were undertaken using R (SmoothHazard); all
other analyses used Stata version 14. A two-sided P-value < 0.05 was con-
sidered statistically significant.
Results
Analysis of cognitive decline
A total of 7428 participants were included in the analysis, characteris-
tics in 1997–1999 presented in Table 1. A total of 43% of participants
had data at all four assessments, 29% at three, 15% at two and 13% at
only one assessment; a total of 414 cases of AF were used in the
analysis.
The age range of participants at the beginning and end of follow-up
was 45–69 years and 61–83 years; mean follow-up was 14.7 years
and annual decline in global cognitive function was -0.050 SD (-0.054,
-0.046). Excess cognitive decline, averaged across all age-groups, in
analysis adjusted for all confounders (Model 2) was greater in those
with AF for longer, P= 0.01 (Table 2 and Figure 1). Incident stroke
(Model 3), or CHD (Model 4) over the follow-up did not explain the
excess decline. However, when both stroke and CHD (Model 5)
were taken into account, the estimate for excess cognitive decline in
those with AF was no longer statistically significant. The interaction
term to test whether the effect of AF duration on cognitive decline
changed with age did not suggest differences (P> 0.05), despite stron-
ger associations in the youngest and oldest participants (Table 2).
Furthermore, consideration of the incidence of stroke and CHD
(model 5) attenuated associations in all but the youngest group (15
years difference in decline = -0.27; 95% CI: -0.51, -0.03).
Supplementary material online, Tables S1 and S2 and Figure S3
show these results separately for the tests of memory, reasoning, and
fluency; there were no associations with memory, even in the mini-
mally adjusted model (Supplementary material online, Table S1).
Analysis of dementia
Of a total of 10 214 persons, followed over a mean 26.6 years, there
were 912 cases of incident AF and 324 cases of dementia; 73% of the
latter recorded in the last 5 years of follow-up. The mean (SD) age at
incident AF and dementia diagnosis was 68.5 (7.7) and 74.9 (5.4)
years, respectively. Table 3 shows that in analysis adjusted for all con-
founders (Model 2), those with AF had 87% excess risk (95% CI: 1.37,
2.55) of dementia. The association was somewhat stronger, albeit
not statistically significant, in those with incident AF before 70 years
(Table 3).
In multistate models, AF was associated with a 6.22 times
increased risk of stroke (95% CI: 4.74, 8.16) and its association with
dementia was not fully explained by stroke as demonstrated by the
increased risk of dementia in those free of stroke (HR = 1.67; 95% CI:
1.17, 2.38), Figure 2A. Further analysis showed AF to increase risk of
CHD (HR = 5.29; 95% CI: 4.50, 6.22; Figure 2B) and CVD (HR = 5.74;
95% CI: 4.95, 6.65; Figure 2C). The analysis of CVD (Figure 2C) shows
that the association between AF and dementia was present in those
with CVD (HR = 1.79; 95% CI: 1.04, 3.08) but not in those free of
CVD (HR = 1.29; 95% CI: 0.74, 2.24).
Discussion
Our study of cognitive decline over 15 years in adults aged 45–69
years at the start of follow-up shows greater cognitive decline in
those with longer exposure to AF. Stroke occurring after the onset
on AF did not explain this excess decline but when both stroke and
CHD over the follow-up were taken into account the association
between duration of exposure to AF and cognitive decline was no
longer statistically significant. This finding was replicated in analysis of
dementia where stroke explained only part of the association of AF
with dementia. Importantly, these findings relate to incident AF in rel-
atively young adults as more than two thirds of AF cases in our analy-
sis occurred before 75 years of age.
.................................................................................................
Table 1 Sample characteristics at the start of cogni-
tive testing (1997–1999)
No AF AF P*
N 7014 414
Male, % 69.7 84.3 <0.001
Age (years), M (SD) 55.5 (6.0) 58.8 (5.9) <0.001
Education (<secondary school), % 44 45.7 0.64
Ethnicity (white), % 91.3 95.4 0.003
Current smoker, % 10.5 8.7 0.29
Heavy alcohol consumption,a % 25 32.1 0.001
Poor diet,b % 27.9 24.9 0.42
Physically inactive,c % 18.2 13.5 0.004
Diabetes, % 4.3 5.6 0.21
Hypertension, % 28 43.7 <0.001
CVD, % 5.1 12.8 <0.001
CVD medication,d % 6.1 14.7 <0.001
Heart failure, % 0.04 0 0.68
M, mean; SD, standard deviation; AF, atrial fibrillation; CVD, cardiovascular
disease.
*P for heterogeneity.
aHeavy alcohol consumption was defined as 14þ units/week in women and
21þ units/week in men.
bCorresponds to fruit and vegetable consumption <once a day.
cCorresponds to <1 h/week of moderate and <1 h/week of vigorous physical
activity.
dCVD medication includes antihypertensives, lipid lowering drugs, nitrates, anti-
platelets, and anticoagulants.
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AF is a common disorder in the elderly,17 its prevalence increases
with age, doubling every decade of life after the age of 50 years to
reach 10–20% after the age of 80 years. As the prevalence of demen-
tia also increases with age, its association with AF has sometimes
been attributed to common age-related mechanisms. However,
increasing evidence of associations with cognitive decline suggests
that AF may indeed be a risk factor for cognitive dysfunction.18 To
the best of our knowledge, few studies have been able to use serial
cognitive testing, starting in mid-life to assess the impact of AF. We
show that even in adults aged 60 years, those with incident AF at age
50 and 55 years had accelerated cognitive decline.
The effect of duration of AF has been examined in relation to
dementia where the associations appear to be stronger in those
with younger age of AF onset.19–21 Stronger effects associated
with longer duration of AF have also been seen for pre-stroke
cognitive impairment,8 and total brain and grey matter volume.22
AF is associated with cerebral hypoperfusion and is a known cause
of embolic stroke, from thrombus originating in the atrial append-
age. It is possible that longer duration of exposure allows a greater
time window for damage from chronic hypoperfusion and devel-
opment of emboli and cardiac failure. AF alters atrial size, sub-
strate, and cardiac function, which develop very early after
....................................................................................................................................................................................................................
Table 3 Association of atrial fibrillation (AF) with incidence of dementia
Model 1 Model 2
Atrial fibrillation N total N cases HR (95% CI) HR (95% CI)
No 9302 274 1.00 1.00
Yes 912 50 1.93 (1.42, 2.63) 1.87 (1.37, 2.55)
Analysis stratified by age of onset of AF
No 9302 274 1.00 1.00
AF before age 70 500 21 2.15 (1.37, 3.37) 2.11 (1.35, 3.32)
AF after age 70 412 29 1.79 (1.20, 2.65) 1.72 (1.15, 2.55)
P for interaction 0.50 0.45
Model 1: Analysis adjusted for age, sex, education, and ethnicity.
Model 2: Model 1þ alcohol consumption, smoking, physical activity, diet, diabetes, hypertension, heart failure, CVD (stroke or CHD), and CVD medication at baseline.
N 
observaons
<=55 
years
55-60
years
60-65 
years
65-70 
years
70-75 
years
75-80 
years
80-85 
years
No AF 4084 4257 5467 4197 2443 1123 165
AF 17 58 127 162 181 134 36
-2
-1
.5
-1
-.5
0
.5
erocSlabol
G
dezidradnatS
50 55 60 65 70 75 80 85
Age (years)
No AF
95% CI, No AF 
50-65 years
60-75 years
70-85 years
p=0.021
p=0.031
p=0.031
Figure 1 Decline in the global cognitive score as a function of atrial fibrillation (AF). *Analysis uses age as the time scale, adjusted for sex, education,
and ethnicity. P-values represent the test for trend for greater effects on cognitive decline in longer exposure to AF.
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diagnosis, and increases the risk of macro- and micro-cerebral
ischaemic events.
The association of AF with cognitive impairment,6,23cognitive
decline,24 hippocampal atrophy,25and dementia,26 appears to be
independent of stroke history. We extended these findings by con-
sidering stroke occurring after AF to show that it does not explain
associations with cognitive decline and dementia. A third of those
with AF have silent infarction27 and cerebrovascular thrombo-embo-
lism together with global brain hypoperfusion due to impaired car-
diac haemodynamics, may account for the increased risk of
developing dementia in AF patients. Our findings highlight the impor-
tance of CVD in the association of AF with cognitive outcomes. The
association of AF with dementia in our study is similar to that in pre-
vious studies,20,26 particularly studies that examined AF onset at
younger ages.19 It remains unclear whether it affects risk of all types
of dementia; one study found evidence of stronger associations with
Alzheimer’s disease,20 another showed the type of dementia not to
matter,19 while MRI data associations with lower total grey matter
but not neurodegenerative changes characteristic of Alzheimer’s
disease.27
The main strengths of our study include the large sample size, con-
sideration of both cognitive decline and dementia, modelling of time
lived with AF, and explicit analysis of the role played by stroke and
CHD after AF onset—an important consideration given the strong
association of AF with these conditions. Our results on the interac-
tion effects with age suggest that that the effect of AF on cognitive
decline is not confined to older ages. We present results using the
global cognitive score, allowing replication across studies in the
future. We have previously shown the risk factor-CHD associations
in our study to be similar to that in a general population study,28 sug-
gesting that the present findings are generalizable.
Limitations of the study include the method of dementia ascertain-
ment, which has high specificity but is unlikely to be sensitive. The fact
that dementia tracing was available on all participants in the study
allows the study results to be free from attrition and selection biases
that are common in studies on older adults. Furthermore, the AF-
CVD association in our study was similar to that in other studies,2
suggesting that case definitions for both conditions are valid. We
were not able to distinguish paroxysmal from persistent AF, in pre-
vious studies the latter was more strongly associated with silent cere-
bral ischaemia and worse cognitive function,23 and higher incidence
of adverse cardiovascular outcomes even in patients treated by anti-
coagulated therapy.29 We were also limited by the smaller number of
patients with AF, particularly in subgroup analysis (e.g. those with inci-
dent CVD) that resulted in broad confidence limits.
In sum, AF is the most common arrhythmia and its most well
established consequence is stroke. With ageing of populations its
impact on cognitive impairment and dementia has become increas-
ingly important and understanding this association has relevance for
the development of preventive and therapeutic strategies.30 AF can
be treated with antiarrhythmic medication, cardioversion, or catheter
ablation. Furthermore, thrombo-prophylaxis with oral anticoagula-
tion is effective in reducing stroke risk, whether the same is true for
dementia is unknown. The present longitudinal study shows that
early onset AF and its duration matters for cognitive decline and
dementia and highlight the importance of effectively treating cardio-
vascular disease in AF patients.1 In those with early age of AF onset, a
longer exposure period might lead to changes that produce greater
neuronal injury and loss, possibly due to the interaction of degenera-
tive and vascular changes.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Start of
Follow-up
Incident 
CHD
Incident
Demena
a. HR=5.29 (95% CI: 4.50, 6.22)
Start of
Follow-up
Incident 
Stroke
Incident 
Demena
a. HR=6.22 (95% CI: 4.74, 8.16)
Start of
Follow-up
Incident 
Stroke/CHD
Incident
Demena
a. HR=5.74 (95% CI: 4.95, 6.65)
A
B
C
Figure 2 Multistate models for the role of atrial fibrillation in
transitions* to stroke (A), CHD (B), stroke or CHD (C), and demen-
tia. *Role of AF (time varying) in the risk of transitions from: (a)
Healthy to stroke (A), CHD (B), and CVD (stroke or CHD, C); (b)
Stroke (A, N (AF/Stroke) = 78/352), CHD (B, N (AF/CHD) = 179/
1790), and CVD (Stroke or CHD, C, N (AF/CVD) = 217/2024) to
dementia; (c) Healthy to dementia in those free of Stroke (A), CHD
(B), and CVD (Stroke or CHD, C). Analyses with age as timescale
and adjusted for sex, education, ethnicity, alcohol consumption,
smoking, physical activity, diet, diabetes, hypertension, heart failure,
CVD, and CVD medication at baseline.
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